Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jonathan M. Poole appointed to ACAD Board effective March 3, 2026 as Class II director; term expires at 2027 Annual Meeting.
ACADIA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jonathan M. Poole appointed to ACAD Board effective March 3, 2026 as Class II director; term expires at 2027 Annual Meeting
- Annual cash compensation: $50,000 board retainer + $12,500 Audit Committee retainer, prorated
- Initial equity grant: $200,000 target fair value (50/50 options/RSUs), vesting equally over 3 years
- Prorated annual equity grant: $95,300 target fair value (50/50 options/RSUs), vesting over ~1 year
- Ongoing annual equity grants from 2026 AGM: $400,000 target fair value (50/50 options/RSUs)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACADIA PHARMACEUTICALS INC 8-K filings
Get the next ACAD 8-K as it lands
Follow ACAD for push alerts, or ask the research agent what this filing means.